Aquestive Therapeutics, Inc. AQST OID and Deferred Financing Cost
OID and Deferred Financing Cost at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:DeferredTaxAssetsOIDAndDeferredFinancingCost.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s oid and deferred financing cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s OID and deferred financing cost?
- Aquestive Therapeutics, Inc. (AQST) reported OID and deferred financing cost of $2M in Q4 2025.
- What does OID and deferred financing cost mean?
- This represents the deferred tax asset associated with Original Issue Discount (OID) and costs incurred to secure financing that are amortized over the life of the debt. These items create temporary differences between book and tax accounting, resulting in future tax benefits as the costs are deducted. It provides insight into the tax-adjusted cost of the company's debt structure.